UCB - ConfometRx Collaborate - Analyst Blog
February 21 2013 - 11:40AM
Zacks
UCB (UCBJF)
recently entered into an agreement with ConfometRx for the
discovery of novel medicines in the neuroscience therapeutic area.
This research and development (R&D) collaboration, spanning two
years, will harness structural biology to gain insight into G
protein coupled receptors (GPCRs) modulation in making drugs.
ConfometRx is developing a platform
of structure-based drug discovery technologies to facilitate lead
identification and lead optimization for GPCR.
UCB also has R&D alliances with
Harvard. UCB and Harvard have three collaborative R&D projects
since 2011. In Oct 2012, the third project was signed to study the
microbiome in the human intestine, classifying new species and
studying their impact on the immune system in order to identify new
drugs for preventing or treating immunological diseases. For this
study, UCB will provide Harvard up to $4.5 million.
The major neuroscience products at
UCB include Vimpat (lacosamide) and Neupro (rotigotine). Vimpat and
Neupro revenues for the nine months ending Sep 30, 2012 were € 237
million and € 93 million respectively.
In Dec 2012, UCB received Japanese approval for Neupro for
Parkinson’s disease and restless legs syndrome. The drug was
approved in the EU and US in 2006 and 2007, respectively.
Vimpat was first launched in the EU in Sep 2008, as an adjunctive
therapy for treating adults and adolescents (16-18 years) suffering
from partial-onset seizures (with or without secondary
generalization) with epilepsy.
Earlier this month, Vimpat was approved in the EU as a single
loading dose option for treating patients suffering from partial
onset seizures.
UCB carries a Zacks Rank #3 (Hold).
Currently, companies like Lannett Company, Inc.
(LCI), SIGA Technologies, Inc. (SIGA) and
United Therapeutics Corporation (UTHR) look more
attractive with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
SIGA TECH INC (SIGA): Free Stock Analysis Report
(UCBJF): ETF Research Reports
UTD THERAPEUTIC (UTHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
London Clubs (AMEX:LCI)
Historical Stock Chart
From Jul 2023 to Jul 2024